Business Overview: Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB)

---

Executive Summary

Anebulo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing therapies to treat acute cannabinoid intoxication (ACI), a condition arising when individuals — particularly children who accidentally ingest cannabis edibles, or adults who overconsume high-potency cannabis products — experience severe, sometimes medically dangerous symptoms including panic, psychosis-like effects, and cardiovascular distress. Anebulo's lead candidate, selonabant, is a cannabinoid receptor type 1 (CB1) antagonist designed to rapidly reverse the acute effects of THC intoxication.

Anebulo is targeting a genuine, currently unaddressed medical need: as of today, there is no FDA-approved treatment specifically for acute cannabinoid intoxication, an increasingly relevant clinical scenario given the continued legalization and rising potency of cannabis products, as well as rising rates of accidental pediatric cannabis edible ingestion.

---

1. Core Business Model & How They Work

As a clinical-stage biotech, Anebulo's model centers on advancing selonabant through clinical trials to establish it as the first approved treatment specifically for acute cannabinoid intoxication:

[ CB1 Receptor Antagonist Design (Selonabant) ] ➡️ [ Phase 1/2 Safety & Proof-of-Concept Trials ] ➡️ [ Pivotal Trial in Acute Cannabinoid Intoxication ] ➡️ [ FDA Approval Pathway (Potential Expedited Designations) ] ➡️ [ Commercialization via Emergency Departments / Poison Control Pathways ]

Key Operational Drivers

1. First-in-Category Opportunity: With no FDA-approved treatment currently available for acute cannabinoid intoxication, Anebulo has the opportunity to be first-to-market in a clearly defined, currently unmet clinical need, rather than competing against existing approved therapies.
2. CB1 Antagonism Mechanism: Selonabant is designed to directly counteract THC's activation of CB1 receptors, aiming to rapidly reverse acute intoxication symptoms — a targeted pharmacological approach rather than generic supportive/sedative care (the current standard of care in emergency settings).
3. Rising Addressable Need: Continued state-level cannabis legalization, increasing product potency, and rising rates of accidental pediatric edible ingestion have expanded the population potentially in need of an effective acute intervention, a favorable long-term market backdrop for the company's target indication.
4. Capital Markets Dependence: As a pre-revenue clinical-stage biotech, Anebulo funds its trials through equity capital markets, a common funding structure and risk factor for companies of its size and stage.

---

2. Competitive Landscape

Key Competitors

• Current standard of care (no direct pharmacological competitor): Emergency departments currently manage acute cannabinoid intoxication with supportive care (sedatives, anti-anxiety medications, anti-nausea treatment) rather than a targeted reversal agent, meaning Anebulo's most direct "competitor" is the absence of a specific approved treatment rather than another company's drug.
• Other CB1 antagonist/cannabinoid-related drug developers: A small number of other biotech and academic programs have explored CB1 antagonism or related mechanisms for various indications (including historically for obesity, before safety concerns led to earlier CB1 antagonists like rimonabant being withdrawn from certain markets), representing potential future competitive or scientific reference points.

Dynamics

Anebulo's competitive positioning is unusual for a biotech in that its most direct competition is the current lack of a specific pharmacological treatment, rather than an established branded or generic competitor — meaning successful clinical validation and regulatory approval would likely provide a meaningful first-mover commercial position, assuming Anebulo can also address historical safety concerns associated with earlier-generation CB1 antagonists.

---

3. Strategic Strengths & Risks

Competitive Strengths (The Moat)

• First-mover opportunity in an indication with no currently approved pharmacological treatment, providing a potentially clear regulatory and commercial path if trials are successful.
• Addresses a well-defined, clinically significant unmet need (emergency treatment of acute cannabinoid intoxication) with rising real-world relevance given cannabis legalization trends.
• Patent protection around selonabant's specific formulation and use in this indication.

Strategic Risks

1. Binary Clinical and Regulatory Risk: As with all clinical-stage biotechs, a failed pivotal trial would be a major setback to the company's core value proposition.
2. Historical CB1 Antagonist Safety Concerns: Earlier-generation CB1 antagonists (e.g., rimonabant, developed for obesity) were associated with psychiatric side effects that led to market withdrawal in some regions, creating a regulatory and clinical bar that Anebulo must clearly address for selonabant.
3. Capital Requirements: Continued trial funding requires ongoing equity capital access, a common dilution risk for small-cap clinical-stage biotechs.
4. Market Size and Commercial Model Uncertainty: As a novel, first-in-category emergency-use indication, the ultimate commercial pathway (e.g., hospital/emergency department stocking, reimbursement dynamics) carries some uncertainty relative to more established chronic disease drug markets.

---

4. Financial Overview

---

5. Summary Conclusion

Anebulo Pharmaceuticals is pursuing a genuinely differentiated, first-in-category opportunity — a specific pharmacological treatment for acute cannabinoid intoxication — addressing a real and, given cannabis legalization and rising product potency trends, growing unmet clinical need with no currently approved competitor.

The company's long-term prospects depend on successfully demonstrating that selonabant can safely and effectively reverse acute THC intoxication in pivotal trials, while addressing the regulatory scrutiny that CB1-targeting mechanisms have faced historically, all funded through continued access to biotech capital markets.